Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis
Toleranzia previously reported the successful completion of a GLP-toxicology study of TOL2, a regulatory milestone for approval of an investigational new drug for first in human testing. To further establish the safety of TOL2, the company recently performed an additional and unique safety study in human tissue.
In this study, blood samples from six MG patients were individually exposed to different concentrations of TOL2 in a system at 37°C mimicking the normal human blood circulation. This safety study is aimed to assess unwanted immune system activation and effects on blood cells.
The results from this patient-based test system identified no signals of inflammatory immune activation or negative effects on blood cell counts attributable to TOL2 at the doses tested.
“We are very excited about the positive results from this study in which we had an exceptional opportunity to test TOL2 directly in samples from our target patient population. This adds highly valuable and relevant information on the safety profile of TOL2 in preparation for the upcoming clinical study in MG patients”, comments Charlotte Fribert, CEO of Toleranzia.
For further information, please contact
Charlotte Fribert – CEO, Toleranzia AB
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that utilize the immune system’s own power to treat autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, only reduce the symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company’s Certified Adviser.